Agenus (AGEN) Competitors $5.96 -0.08 (-1.32%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$5.93 -0.03 (-0.50%) As of 07/25/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AGEN vs. ZBIO, RGLS, LXRX, MYGN, EBS, RIGL, XOMA, VSTM, VNDA, and CBIOShould you be buying Agenus stock or one of its competitors? The main competitors of Agenus include Zenas BioPharma (ZBIO), Regulus Therapeutics (RGLS), Lexicon Pharmaceuticals (LXRX), Myriad Genetics (MYGN), Emergent Biosolutions (EBS), Rigel Pharmaceuticals (RIGL), XOMA Royalty (XOMA), Verastem (VSTM), Vanda Pharmaceuticals (VNDA), and Crescent Biopharma (CBIO). These companies are all part of the "biotechnology" industry. Agenus vs. Its Competitors Zenas BioPharma Regulus Therapeutics Lexicon Pharmaceuticals Myriad Genetics Emergent Biosolutions Rigel Pharmaceuticals XOMA Royalty Verastem Vanda Pharmaceuticals Crescent Biopharma Zenas BioPharma (NASDAQ:ZBIO) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings. Do analysts prefer ZBIO or AGEN? Zenas BioPharma presently has a consensus target price of $36.67, indicating a potential upside of 134.14%. Agenus has a consensus target price of $16.33, indicating a potential upside of 174.05%. Given Agenus' higher probable upside, analysts plainly believe Agenus is more favorable than Zenas BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zenas BioPharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Agenus 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the media refer more to ZBIO or AGEN? In the previous week, Agenus had 2 more articles in the media than Zenas BioPharma. MarketBeat recorded 3 mentions for Agenus and 1 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 1.52 beat Agenus' score of 0.62 indicating that Zenas BioPharma is being referred to more favorably in the media. Company Overall Sentiment Zenas BioPharma Very Positive Agenus Positive Which has preferable valuation and earnings, ZBIO or AGEN? Zenas BioPharma has higher earnings, but lower revenue than Agenus. Zenas BioPharma is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZenas BioPharma$5M131.01-$156.99M-$3.55-4.41Agenus$103.46M1.58-$227.21M-$8.67-0.69 Is ZBIO or AGEN more profitable? Zenas BioPharma has a net margin of 0.00% compared to Agenus' net margin of -196.12%. Company Net Margins Return on Equity Return on Assets Zenas BioPharmaN/A N/A N/A Agenus -196.12%N/A -82.33% Do institutionals and insiders believe in ZBIO or AGEN? 61.5% of Agenus shares are owned by institutional investors. 16.5% of Zenas BioPharma shares are owned by insiders. Comparatively, 5.5% of Agenus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryZenas BioPharma beats Agenus on 9 of the 14 factors compared between the two stocks. Get Agenus News Delivered to You Automatically Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AGEN vs. The Competition Export to ExcelMetricAgenusMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$165.60M$3.06B$5.69B$9.50BDividend YieldN/A2.37%4.58%4.01%P/E Ratio-0.6921.1828.1020.05Price / Sales1.58288.50432.4490.07Price / CashN/A42.7636.2258.56Price / Book-0.468.378.665.87Net Income-$227.21M-$55.19M$3.25B$258.55M7 Day Performance-3.09%5.88%4.23%3.74%1 Month Performance21.38%17.33%10.52%11.75%1 Year Performance-9.15%4.42%34.41%18.03% Agenus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AGENAgenus4.2207 of 5 stars$5.96-1.3%$16.33+174.0%-0.1%$165.60M$103.46M-0.69440ZBIOZenas BioPharma1.6642 of 5 stars$14.29+4.1%$36.67+156.6%N/A$597.75M$5M-4.03N/ANews CoverageRGLSRegulus Therapeutics1.5038 of 5 stars$8.16flat$8.50+4.2%N/A$564.92MN/A-11.1830LXRXLexicon Pharmaceuticals2.5712 of 5 stars$1.23flat$3.67+198.1%-52.8%$444.63M$31.08M-2.41140MYGNMyriad Genetics4.6737 of 5 stars$4.45-0.4%$14.38+223.2%-84.0%$410.20M$837.60M-3.972,700News CoveragePositive NewsEBSEmergent Biosolutions4.3367 of 5 stars$6.93+0.0%$14.33+106.8%-48.2%$376.27M$1.04B-2.562,420News CoveragePositive NewsRIGLRigel Pharmaceuticals3.2084 of 5 stars$19.59+4.2%$36.40+85.8%+85.0%$350.07M$179.28M9.46160Positive NewsXOMAXOMA Royalty4.011 of 5 stars$25.48-0.7%$69.50+172.8%-10.7%$305.00M$28.49M-22.1610News CoverageAnalyst UpgradeVSTMVerastem3.5296 of 5 stars$5.10-1.2%$13.38+162.3%+106.7%$280.24M$10M-1.5950VNDAVanda Pharmaceuticals4.7402 of 5 stars$4.66-2.5%$16.50+254.1%-22.9%$274.61M$198.77M-6.21290Upcoming EarningsCBIOCrescent Biopharma3.2077 of 5 stars$13.20-1.0%$25.67+94.4%N/A$258.06M$10K-0.2950High Trading Volume Related Companies and Tools Related Companies Zenas BioPharma Alternatives Regulus Therapeutics Alternatives Lexicon Pharmaceuticals Alternatives Myriad Genetics Alternatives Emergent Biosolutions Alternatives Rigel Pharmaceuticals Alternatives XOMA Royalty Alternatives Verastem Alternatives Vanda Pharmaceuticals Alternatives Crescent Biopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AGEN) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agenus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agenus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AGEN Stock Alerts